公开(公告)号：US12053514B2

公开(公告)日：2024-08-06

申请号：US14489182

申请日：2014-09-17

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony Yu ,  Cheng-Chi Irene Wang ,  Wei-Han Lee ,  Yu-Chen Lin ,  Yu-Hsin Tom Lin ,  I-Ju Chen

IPC分类号： A61K39/00 ,  A61K47/64 ,  G01N21/64

CPC分类号： A61K39/001173 ,  A61K47/643 ,  A61K47/646 ,  G01N21/64 ,  A61K2039/55577 ,  A61K2039/6081 ,  A61K2039/627 ,  A61K2039/64

摘要： The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

公开(公告)号：US20180264093A1

公开(公告)日：2018-09-20

申请号：US15761301

申请日：2016-09-14

申请人： MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION ,  DCB-USA, LLC

发明人： Chih-Long CHANG ,  Chao-Chih WU

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K9/0019 ,  A61K38/00 ,  A61K39/00 ,  A61K39/001169 ,  A61K39/001171 ,  A61K39/001173 ,  A61K39/00118 ,  A61K39/39558 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/55583 ,  A61K2039/605 ,  A61K2039/62 ,  A61K2039/70 ,  A61P35/00 ,  C07K16/30 ,  C07K16/3076

摘要： Disclosed herein are immunogenic glycopeptide compounds for inducing immune responses to prevent and/or treat cancer. Other aspects of the present disclosure are pharmaceutical compositions comprising the immunogenic glycopeptide compounds, and methods using the compounds for preventing and/or treating a cancer in a subject.

公开(公告)号：US12023379B2

公开(公告)日：2024-07-02

申请号：US17132320

申请日：2020-12-23

申请人： Emory University

发明人： Periasamy Selvaraj

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/385 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001106 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/00117 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001191 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/39 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/6018 ,  A61K2039/62 ,  A61K2039/627

摘要： In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

公开(公告)号：US20240139301A1

公开(公告)日：2024-05-02

申请号：US18253576

申请日：2021-11-19

申请人： OBI Pharma, Inc.

发明人： Ming-Tain LAI ,  Cheng-Der Tony YU ,  I-Ju CHEN ,  Wei-Han LEE ,  Chueh-Hao YANG ,  Chun-Yen TSAO ,  Chang-Lin HSIEH ,  Chien-Chih OU ,  Chen-En TSAI

IPC分类号： A61K39/00 ,  A61K45/06 ,  A61K47/64 ,  A61P35/00

CPC分类号： A61K39/001173 ,  A61K45/06 ,  A61K47/646 ,  A61P35/00 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/86

摘要： The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

公开(公告)号：US20240092932A1

公开(公告)日：2024-03-21

申请号：US18506571

申请日：2023-11-10

申请人： The University of Toledo

发明人： Peter Andreana ,  Kevin Trabbic ,  Mengchao Shi ,  Jean Paul Bourgault

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K47/61 ,  A61K47/68 ,  A61P35/00 ,  C12N5/12

CPC分类号： C07K16/30 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/39 ,  A61K39/39558 ,  A61K47/61 ,  A61K47/6855 ,  A61P35/00 ,  C12N5/12

摘要： Entirely carbohydrate immunogens, monoclonal antibodies generated from immune responses to entirely carbohydrate immunogens, vaccine compositions, pharmaceutical compositions, and methods of making and using the same, are described.

公开(公告)号：US11642400B2

公开(公告)日：2023-05-09

申请号：US15662162

申请日：2017-07-27

申请人： OBI PHARMA, INC.

发明人： Cheng-Der Tony Yu ,  Peiwen Yu ,  Kuo-Pao Lai ,  Wei-Han Lee ,  I-Ju Chen ,  Shu-Yi Lin ,  Yih-Huang Hsieh

IPC分类号： A61K39/00

CPC分类号： A61K39/0011 ,  A61K39/00118 ,  A61K39/001173 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55577 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  A61K2039/64

摘要： The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.